## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($925.40)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Guggenheim Maintains Buy on Eli Lilly (LLY) After "Another Impressive Year"**
- Source: Finviz | 20251208T123600 | Bullish | Relevance: 99%
- Guggenheim has reiterated its "Buy" rating on Eli Lilly (NYSE: LLY) and increased its price target to $1,163, citing the company's "impressive year" in 2025 driven by strong execution and its leadership in the weight loss drug market. Eli Lilly's exceptional financial performance, particularly its Mounjaro and Zepbound drugs, and the promising results of its potential weight loss pill, orforglipron, underscore the firm's confidence in the company's continued growth. The company reported $17.6 billion in Q3 2025 revenue, a 53.8% increase year-over-year, significantly beating analyst estimates.

**2. Eli Lilly lands in Huntsville with $6 billion mega-site, thousands of jobs and a Made-in-America medicine push**
- Source: Yellowhammer News | 20251209T212058 | Bullish | Relevance: 98%
-  Eli Lilly and Company is investing over $6 billion to build a new pharmaceutical manufacturing facility in Huntsville, Alabama, marking the largest initial investment in the state's history. This mega-site will create approximately 3,450 jobs and focus on domestic production of "small molecule synthetic and peptide medicines," including orforglipron. The project reinforces a "Made in America" push for medicines and is expected to significantly boost local economic activity.

**3. Bank of Nova Scotia Grows Stock Holdings in Eli Lilly and Company $LLY**
- Source: MarketBeat | 20251208T090830 | Bullish | Relevance: 98%
-  Bank of Nova Scotia increased its stake in Eli Lilly and Company by 0.6% in Q2, acquiring an additional 1,376 shares, bringing its total to 248,260 shares valued at approximately $193.5 million. This increase comes as analysts have become more bullish on the stock, with several upgrades and raised price targets. Eli Lilly also reported strong Q3 earnings, exceeding revenue and EPS expectations, and declared a quarterly dividend of $1.50 per share.

**4. Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025**
- Source: Oncodaily | 20251209T110858 | Bullish | Relevance: 98%
-  Eli Lilly and Company announced the reappointment of Dr. Carolyn R. Bertozzi to its Board of Directors, effective December 8, 2025. Dr. Bertozzi, a Nobel laureate, will serve on the Science and Technology Committee and the Ethics and Compliance Committee, reinforcing Lilly's commitment to scientific excellence and ethical leadership. Her return is expected to significantly contribute to the company's therapeutic innovations, particularly in oncology and immunology.

**5. Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025**
- Source: Oncodaily | 20251209T110822 | Bullish | Relevance: 98%
-  Eli Lilly and Company announced the re-election of Nobel laureate Carolyn R. Bertozzi, Ph.D., to its Board of Directors, effective December 8, 2025. Dr. Bertozzi, known for her pioneering work in bioorthogonal chemistry, will serve on the Science and Technology Committee and the Ethics and Compliance Committee. Her return is expected to reinforce Lilly's commitment to scientific excellence and ethical leadership, leveraging her insights in targeted medicine and drug development.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |
| 2025-11-24 | Bernstein | $1300 | $1100 | +18% |
| 2025-11-19 | Truist Securiti | $1182 | $1038 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |
| 2025-11-24 | Bernstein | main | Outperform |
| 2025-11-19 | Truist Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($2.11M) |
| Sells | 30 ($207.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.5% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $208M sold (30 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 9 raises (avg +16%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.90 indicates undervaluation relative to growth. Forward P/E 30.5x attractive for 36% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Analyst sentiment positive (9 raises, avg +16%). Insider selling cluster ($208.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $880.5B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.90 |
| Forward P/E | 30.5 |
| Current P/E | 41.5 |
| YoY Growth | 35.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -5.1% to -6.6% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.6pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.21x) but short-term weakness (below SMA20). MACD histogram bearish (-17.07), momentum weakening. RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.60% (CS: 3) | Weak |
| RSI_14 | 46.9 | Neutral |
| MACD Histogram | -17.07 | Bearish |
| vs SMA20 | 0.946x | Below |
| vs SMA50 | 1.065x | Above |
| vs SMA200 | 1.208x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $982.22
- **Stop Loss:** $925.40 (5.8% risk)
- **Target:** $1039.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 5
- **Position Value:** $4,911.10
- **Portfolio %:** 4.91%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*